证券代码：688293 证券简称：奥浦迈 公告编号：2023-017 上海奥浦迈生物科技股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩说明会的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2023年6月7日（星期三）下午13:00-14:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于2023年05月31日(星期三)至06月06日(星期二)16:00前登录上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 IR@opmbiosciences.com进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 上海奥浦迈生物科技股份有限公司（以下简称"奥浦迈"或"公司"）已分别于 2023年3月30日发布公司《2022年年度报告》、2023年4月28 ...

Financial Performance - The company's operating revenue for Q1 2023 was CNY 67,917,690.55, representing a decrease of 6.53% compared to the same period last year[5]. - The net profit attributable to shareholders was CNY 24,191,151.59, down by 4.26% year-on-year[5]. - The net profit after deducting non-recurring gains and losses was CNY 21,054,676.90, reflecting an 11.50% decline compared to the previous year[5]. - In Q1 2023, the total revenue was CNY 67,917,690.55, a decrease of 6.5% compared to CNY 72,665,072.90 in Q1 2022[25]. - The net profit for Q1 2023 was CNY 24,065,980.32, compared to CNY 25,268,632.49 in Q1 2022, indicating a decline of 4.8%[25]. - The net profit attributable to the parent company for Q1 2023 is CNY 24,191,151.59, a decrease of 4.3% compared to CNY 25,268,632.49 in Q1 2022[26]. - The basic and diluted earnings per share for Q1 2023 are CNY 0.30, down from CNY 0.41 in Q1 2022, representing a decline of 26.8%[26]. Cash Flow - The net cash flow from operating activities increased significantly by 90.86%, amounting to CNY 4,496,312.41[5]. - Cash inflow from operating activities for Q1 2023 is CNY 64,579,092.78, an increase of 21.0% from CNY 53,366,977.29 in Q1 2022[28]. - The net cash flow from operating activities for Q1 2023 is CNY 4,496,312.41, up from CNY 2,355,851.35 in Q1 2022, indicating a growth of 90.9%[28]. - Cash outflow from investing activities in Q1 2023 is CNY 361,891,423.70, significantly higher than CNY 25,022,935.96 in Q1 2022[29]. - The net cash flow from investing activities for Q1 2023 is -CNY 90,260,145.10, compared to -CNY 24,322,935.96 in Q1 2022, reflecting a deterioration in investment cash flow[29]. - The net cash flow from financing activities for Q1 2023 is -CNY 3,123,849.50, an improvement from -CNY 5,992,187.60 in Q1 2022[29]. - The total cash and cash equivalents at the end of Q1 2023 is CNY 1,416,319,230.30, compared to CNY 275,189,112.45 at the end of Q1 2022, showing a substantial increase[29]. - The company's cash and cash equivalents decreased to CNY 1,416,319,230.30 as of March 31, 2023, from CNY 1,505,906,562.65 at the end of 2022, a drop of 5.9%[21]. Research and Development - Research and development expenses totaled CNY 9,727,974.76, an increase of 81.11%, accounting for 14.32% of operating revenue, which is an increase of 6.93 percentage points[5]. - The company's R&D investment totaled 9.73 million RMB, accounting for 14.32% of revenue, representing an increase of 81.11% year-over-year[17]. - R&D expenses increased to CNY 9,727,974.76 in Q1 2023, up from CNY 5,371,286.68 in Q1 2022, representing an increase of 80.5%[25]. - As of the end of Q1 2023, the company had 125 confirmed drug development pipelines using its cell culture products, an increase of 14 from the end of 2022[17]. - Among the 125 pipelines, 72 are in the preclinical stage, 25 in Phase I, 10 in Phase II, 17 in Phase III, and 1 in commercial production[18]. Operational Efficiency - The company has strengthened internal management and improved operational efficiency in response to challenges in the biopharmaceutical industry[16]. - The gross profit margin remained high, improving by approximately 1 percentage point compared to the same period last year[16]. - The revenue from cell culture media significantly increased, demonstrating strong resilience in the high-end culture media sector[16]. - The company signed a strategic research cooperation agreement with East China University of Science and Technology in November 2022, establishing a joint research institute[17]. - The company plans to expand its market presence and has resumed some projects that were previously delayed due to adverse market conditions[19]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,352,102,249.90, a slight increase of 0.19% from the end of the previous year[5]. - The total assets as of March 31, 2023, were CNY 2,352,102,249.90, slightly up from CNY 2,347,749,143.04 at the end of 2022[22]. - The company's total liabilities decreased to CNY 142,562,885.63 as of March 31, 2023, from CNY 163,071,138.95 at the end of 2022, a reduction of 12.5%[23]. - The company reported an increase in accounts receivable to CNY 77,863,525.60 as of March 31, 2023, compared to CNY 75,869,111.97 at the end of 2022, an increase of 2.6%[21]. - The company reported a significant increase in accounts receivable by 126.35%, primarily due to an increase in bank acceptance bills received[8]. Strategic Developments - The company is currently constructing a CDMO biopharmaceutical commercialization production platform, expected to enhance service capabilities significantly upon completion in H1 2023[19]. - The company's major IVD clients had temporarily increased their procurement of culture media in Q1 2022, which affected the year-over-year comparison[16]. - The company did not execute any mergers or acquisitions during the reporting period[26]. - The actual controllers of the company hold a combined 31.49% of the shares, with 24.41% directly held by the main shareholder[14].

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the year, representing a 25% growth compared to the previous year[15]. - The company's operating revenue for 2022 was CNY 294,365,734.14, representing a 38.41% increase compared to CNY 212,683,302.44 in 2021[25]. - The net profit attributable to shareholders for 2022 was CNY 105,369,365.72, a significant increase of 74.47% from CNY 60,393,665.20 in 2021[25]. - The net profit after deducting non-recurring gains and losses was CNY 88,797,877.12, up 79.23% from CNY 49,543,382.24 in the previous year[25]. - The company's total assets reached CNY 2,347,749,143.04 at the end of 2022, a 214.26% increase from CNY 747,078,076.82 at the end of 2021[25]. - The net assets attributable to shareholders increased by 288.42% to CNY 2,184,678,004.09 from CNY 562,453,622.16 in 2021[25]. - The company's operating profit reached 115.92 million yuan, up 80.54% year-on-year[132]. - The overall gross margin for the reporting period was 63.97%, with the gross margin for the CDMO business at 40.99%[121]. Dividends and Capital Structure - The company plans to distribute a cash dividend of RMB 6.00 per 10 shares, totaling approximately RMB 49.19 million, which represents 46.68% of the net profit attributable to shareholders for 2022[6]. - The company intends to increase its share capital by 4 shares for every 10 shares held, resulting in a total increase of 32,792,132 shares, raising the total share capital from 81,980,328 to 114,772,460 shares[6]. Governance and Compliance - The company has confirmed that all board members attended the board meeting, ensuring governance compliance[5]. - The company has not violated any decision-making procedures in providing guarantees to external parties[8]. - The company has not disclosed any special arrangements in corporate governance[8]. - The company has established a governance framework consisting of the shareholders' meeting, board of directors, supervisory board, and senior management, ensuring clear responsibilities and coordinated operations[181]. - The company has ensured compliance with legal and regulatory requirements in its decision-making processes[181]. Research and Development - The R&D expenditure as a percentage of operating revenue was 11.28%, up 2.02 percentage points from 9.26% in 2021[26]. - The total R&D investment for the reporting period reached ¥33,195,981.13, representing a 68.60% increase compared to the previous year, and accounting for 11.28% of total revenue[91][92]. - The number of R&D personnel increased from 34 to 52, with the proportion of R&D staff in the total workforce rising from 16.35% to 19.92%[94]. - The company has developed proprietary technologies that allow precise control of culture medium components, enhancing product expression levels[82]. - The company has developed several new cell culture media products, including StarCHO and SagiCHO series, which significantly enhance cell growth and protein expression compared to imported media[86]. Market Expansion and Strategy - The company is expanding its market presence by entering two new international markets, aiming for a 15% market share within the first year[15]. - The company aims to enhance its clinical research capabilities, with plans to initiate Phase II clinical trials for its lead drug candidate in Q4 2023[15]. - The company is focused on expanding its overseas market presence to promote its cell culture products and CDMO services internationally[86]. - The company plans to establish two 500L and two 2,000L antibody production lines in its D3 CDMO factory in 2023, significantly enhancing CDMO service capacity[173]. Risks and Challenges - The company has outlined potential risks in its operations, which are detailed in the report[4]. - The company faces risks related to the stability of raw material supply, with a reliance on a few core suppliers for critical components of its media products[114]. - The company is at risk of potential technology leaks or intellectual property issues, which could adversely affect its core competitiveness[110]. - The company faces risks related to potential contract terminations or payment delays in its CDMO business due to uncertainties in drug research outcomes and market conditions[120]. Customer and Market Engagement - User data showed a 30% increase in the number of active users, reaching 500,000 by the end of the year[15]. - The company has served over 600 domestic and international biopharmaceutical enterprises and research institutions, with a total of 111 drug development pipelines using its cell culture products, an increase of 50.00% from the end of 2021[38]. - The company has established a new partnership with a leading healthcare provider, expected to drive further growth in user acquisition[191]. Financial Health and Investments - The company's cash and cash equivalents increased to 1,202,710,345.67 RMB, primarily due to funds raised from the initial public offering[152]. - The total assets increased significantly, with cash and cash equivalents accounting for 64.14% of total assets, up from 41.54% in the previous year[153]. - The company has a robust procurement system, ensuring stable supply by selecting multiple qualified suppliers for critical raw materials[65]. Future Outlook - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 20% to 1.44 billion RMB[15]. - The company plans to invest 100 million RMB in upgrading its manufacturing facilities to meet GMP standards by the end of 2023[15]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[186].

上海奥浦迈生物科技股份有限公司 2022 年第三季度报告 证券代码：688293 证券简称：奥浦迈 上海奥浦迈生物科技股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | | | 本报告期 | | 年初至报告期 | | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 比上年同 | 年初至报告期 | 末比上年同期 | | | | 期增减变 | 末 | 增减变动幅度 | | | | 动幅度(%) | | (%) | | 营业收入 | 76,391,642.11 | 11 ...